GlassScriptPhysician profile
David James Gibson
NPI 1437498276
$2,317.23
in general payments reported to CMS, 2019-2025
27 companies · $876 in 2025
The $876 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $20.55 · 2023: $643 · 2024: $777 · 2025: $876.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,297.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,296.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $626.00 | 2023-2025 | |
| Glaxosmithkline, LLC. | $196.94 | 2023-2025 | Benlysta, Nucala |
| Amgen INC. | $180.77 | 2022-2025 | Otezla, Enbrel, Otezla |
| Astrazeneca Pharmaceuticals LP | $139.15 | 2023-2025 | Saphnelo |
| Ucb, INC. | $135.30 | 2023-2025 | Rystiggo, Cimzia, Bimzelx |
| Janssen Biotech, INC. | $126.60 | 2023-2025 | Tremfya |
| Lundbeck LLC | $119.88 | 2023-2025 | Vyepti |
| Alexion Pharmaceuticals, INC. | $95.93 | 2023-2025 | Strensiq, Ultomiris |
| Lilly USA, LLC | $82.62 | 2023 | Taltz |
| Teva Pharmaceuticals USA, INC. | $60.61 | 2025 | Austedo Xr, Ajovy |
| Amneal Pharmaceuticals LLC | $58.76 | 2025 | Crexont |
| Genentech USA, INC. | $55.93 | 2024-2025 | Actemra |
| Novartis Pharmaceuticals Corporation | $55.65 | 2023-2024 | |
| Grifols USA, LLC | $48.48 | 2023-2024 | Gamunex-C |
| Pfizer INC. | $45.45 | 2023-2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $38.78 | 2025 | Rexulti |
| Sk Life Science, INC. | $34.55 | 2023-2025 | |
| Emd Serono, INC. | $32.33 | 2023 | Mavenclad |
| Kyowa Kirin, INC. | $31.76 | 2023 | Nourianz |
| Neurocrine Biosciences, INC. | $28.24 | 2025 | |
| Alnylam Pharmaceuticals INC. | $25.90 | 2023 | Onpattro |
| Novo Nordisk INC | $19.36 | 2025 | Wegovy |
| Radius Health, INC. | $19.09 | 2024 | Tymlos |
| Pacira Pharmaceuticals Incorporated | $15.83 | 2024 | Zilretta, Iovera |
| Neurelis, INC. | $14.52 | 2023 | Valtoco |
| Horizon Therapeutics Plc | $14.46 | 2023 | Krystexxa |
| Sumitomo Pharma America, INC. | $14.34 | 2023 | Aptiom |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Gibson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.